Celldex Q2 net loss $0.54 per share; Phase 3 CSU program launched

Celldex Therapeutics, Inc.

2024-Q2 EPS reported -$1.10 revenue$2,654,000

Net loss $35.8M ($0.54/share) vs $30.5M loss in Q2 2023; revenue $2.5M, up from $0.3M.
Cash $802.3M as of June 30; sufficient to fund operations through 2027.
Initiated global Phase 3 CSU trials (EMBARQ-CSU1/2) in July 2024; actively enrolling.
Phase 2 CIndU study met primary endpoint (negative provocation test) at Week 12; full data 2H 2024.
Barzolvolimab Phase 2 studies ongoing in PN, EoE; AD study to start YE 2024; bispecific CDX-622 enters clinic in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.